Global Projections for Diabetes:

Slides:

Advertisements

Similar presentations

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections.

Advertisements

GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 7.

Utilizing Anti-diabetic Agents to Manage Cardiovascular Disease in T2DM Patients James LaSalle, D.O., FAAFP.

Clinical Outcomes with Newer Antihyperglycemic Agents

Case-Based Examination of Treatment Options in Type 2 Diabetes Management.

Clinical Outcomes with Newer Antihyperglycemic Agents

Mikhail Kosiborod, MD Professor of Medicine (Cardiology)

Cardiovascular Challenges in Diabetes

Disclosure Consultations and Honoraria Grant Support

Empagliflozin (Jardiance®)

Diabetes and Risk of CV Outcomes

CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?

CV Risk reduction in T2DM with GLP-1 Agonists: Should We Change Our Clinical Practice?

SGLT2 Inhibitors: What Do the Data Mean for My Patients?

Updates on Emerging GLP-1 Receptor Agonists

Updates on CVOT Data and Clinical Comparisons That Matter

Expert Panelists. Emerging CV Outcomes Trial Results: What Do They Mean for T2D Management?

CV Risk Management in T2DM: What Did We Learn From EASD 2016?

Updates on Outcomes for Novel T2D Therapies

SGLT2 Inhibitors in Phase 3 Trials

Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

Updates Abound.

Examining CV Effects of Basal Insulin Therapy

Novel Developments & Latest Clinical Results With Long-Acting GLP-1 Receptor Agonists.

Looking Beyond Glucose Control: Multifactorial Management of Type 2 Diabetes.

Latest Cardiovascular Outcomes Trials: A Closer Look at the LEADER Results.

Impacting CV Risk With Diabetes Medications

EMPA-REG OUTCOME Trial design: Patients with type 2 diabetes mellitus (DM2) at high risk for CV events were randomized to receive in a 1:1:1 fashion either.

Impacting CV Risk With Diabetes Medications

Clinical Application of New CV Outcomes Data

T2DM and CV Outcomes Trials: A Deep Dive!

A Deep Dive Into CVOTs.

Expert Appraisal of CV Outcome Trial Results in T2DM for the Diabetologist.

ADA/EASD Position Statement: Approach to Hyperglycemia Management

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Diabetes and CV Risk Reduction: Cardiologists’ Perspectives on the Latest Outcomes Data.

SGLT2 inhibitors, Now Part of the Cardiology Toolkit for Comprehensive CV Risk Management.

A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.

UKPDS 34: Metformin vs Conventional Glycemic Control on Outcomes

Case Study Role of DPP-4 Inhibitors

Tackling CV Risk in T2DM.

Early and Intensive T2D Management:

Breaking Down the CVOTs

EXAMINE Study: Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome.

CV Risk Management in T2DM: What Did We Learn from ADA 2016?

Heart Failure Hospitalization Risks with DPP-IV Inhibitors: Myth or Reality?

Type 2 Diabetes Management: Where Are We Heading in Our Efforts to Control CV Risk?

New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.

T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus

LEADER One Year On.

GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?

Learning Objectives Metabolic Abnormalities Associated With T2D.

Novel Approaches to T1D Management

Antihyperglycemic Therapy

T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight

T2DM, CV Risk, and Modulating Risk With Glucose-Lowering Strategies

CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?

Case Challenges: Early and Intensive Type 2 Diabetes Treatment With Modern Agents.

Dual SGLT1/SGLT2 Inhibition in T1D

Updates From ACC.

Patient Selection for Modern T2D Agents

Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?

2015 EASD In Review: CV Risk management in t2dm

Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

New Approaches for Type 2 Diabetes -- GLP-1 RAs Now and in the Future

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS

Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.

The Expanding Role of SGLT Inhibitors Across the Diabetes Spectrum

Presentation transcript:

Global Projections for Diabetes: 2003-2025

Efficacy of DPP-4 Inhibitor Therapy Added to Metformin

DPP-4 Inhibitors vs SUs Added to Metformin: 2-Year Results

Glycemic Control With GLP-1 RAs: Head-to-Head Studies

Efficacy and Safety: SGLT2 Inhibitor vs Sitagliptin (DPP-4 Inhibitor) Added to Metformin

SGLT2 Inhibitor vs SU Added to Metformin

Effect of Liraglutide Dose on Mean Weight Change Response

SGLT2 Inhibitor Pooled Data: Weight Reduction in Placebo-Controlled Studies

SGLT2 Inhibitor: Weight Loss Is Mostly Fat

DPP-4 Inhibitor vs SGLT2 Inhibitor: Effect on SBP in T2DM

SAVOR-TIMI 53: Primary Endpoint

SAVOR-TIMI 53: Hospitalization for HF

EXAMINE: Primary Endpoint

EXAMINE: Hospitalization for HF

TECOS: Effect of Sitagliptin vs Placebo on CV Outcomes in T2DM

TECOS: Hospitalization for HF

EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on the Primary Composite Outcome

EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on CV Death

EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on All-Cause Mortality

EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on HF Hospitalization

DUAL-I: HbA1c Comparison

DUAL-I: Percentage of Patients to Target HbA1c

DUAL-I: Change in Body Weight

DUAL-I: Confirmed Hypoglycemia

DUAL-I: Nausea Over 26 Weeks